KKR & Q3 2026 EPS Tops Estimates at $1.78, but Revenue Misses at $2.61B
Revenue of $2.61B vs. $2.66B expected and adjusted EPS of $1.78 vs. $1.58; revenue down 52% from a year earlier.
KKR & (KKR) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $2.61 billion, down 52% from a year earlier, below the $2.66 billion estimate, and adjusted EPS was $1.78, up 26% from a year earlier, above the $1.58 estimate.
Shares rose 1.0% in premarket trading as of 8:20 a.m. ET, to $97.47 from a $96.48 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $1.58 | $1.78 | Beat by 13% |
| Revenue | $2.66B | $2.61B | Miss by 1.8% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 26% | ▲ 9.2% |
| Revenue | ▼ 52% | ▼ 5.6% |
By our calculation, revenue was $48.6 million below the estimate and adjusted EPS was $0.20 above it. The QoQ column compares with the previous quarter's revenue of $2.76 billion and adjusted EPS of $1.63. The YoY column compares with $5.46 billion and $1.41 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 7 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $5.46 billion, $1.64 billion, $2.35 billion, $2.76 billion and $2.61 billion.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $3.64 and revenue of $2.97 billion next quarter, based on 10 analysts.
- Revenue growth. Whether revenue stabilizes after this quarter's 52% decline from a year earlier to $2.61 billion.
- Estimate record. Whether KKR & extends a record of beating EPS estimates in 7 of its last 8 reports.
- Related coverage. See our reports on Turning Point Brands, ImmunityBio, RB Global and Roivant Sciences.
Sources: Results are from KKR &'s Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from KKR &'s earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Turning Point Brands Beats Q3 2026 Estimates as Revenue Rises 27% to $151.1M
EarningsImmunityBio Misses Q3 2026 Estimates as Revenue Rises 52% to $48.8M
EarningsRB Global Beats Q3 2026 Estimates as Revenue Rises 17% to $1.27B
EarningsRoivant Sciences Beats Fiscal Q2 2026 Estimates as Revenue Rises 1871% to $31.0M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
